Discrepancies between detection of Bcl-2 by in situ hybridization and immunocytochemistry in human prostate cancer tissues

International Journal of Cancer

Volumn 79, Issue 6, 1998, Pages 614-618

  Fiorentino, Michelangelo ^a   D'Errico, Antonia ^a   Barozzi, Chiara ^a   Grigioni, Walter F ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN BCL 2;

ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

ANDROGEN ANTAGONISTS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER;

EID: 0031738429     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981218)79:6<614::AID-IJC10>3.0.CO;2-I     Document Type: Article

References (27)

1. AMERICAN JOINT COMMITEE ON CANCER (AJCC), Manual for staging of cancer (5th ed.), Lippincott, Philadelphia (1997).
2. APAKAMA, I., ROBINSON, M.C., WALTER, N.M., CHARLTON, R.G., ROYDS, J.A., FULLER, C.E., NEAL, D.E. and HAMDY, F.C., Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone- refractory prostate cancer. Brit. J. Cancer, 74, 1258-1262 (1996).
3. BACCARINI, P., FIORENTINO, M., D'ERRICO, A., MANCINI, A.M. and GRIGIONI, W.F., Detection of antisense transcripts of the insulin-like growth factor II (IGF-II) gene in Wilms' tumor. Amer. J. Pathol., 43, 1535-1541 (1993).
4. BONKHOFF, H., Role of the basal cells in premalignant changes of the human prostate: a stem cell concept for the development of prostate cancer. Europ. Urol., 30, 201-205 (1996).
5. BUBENDORF, L., SAUTER, G., MOCH, H., JORDAN, P., BLOCHLINGER, A., GASSER, T.C. and MIHATSCH, M.J., Prognostic significance of Bcl-2 in clinically localized prostate cancer. Amer. J. Pathol., 148, 1557-1565 (1996).
6. CARDILLO, M., BERCHEM, G., TARKINGTON, M.A., KRAJEWSKI, S., KRAJEWSKI, M., REED, J.C., TEHAN, T., ORTEGA, L., LAGE, J. and GELMANN, E.P., Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation. J. Urol., 158, 212-216 (1997).
7. COLOMBEL, M., SYMMANS, F., GIL, S., O'TOOLE, K.M., CHOPIN, D., BENSON, M., OLSSON, C.A., KORSMEYER, S. and BUTTYAN, R., Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers. Amer. J. Pathol., 143, 390-400 (1993).
8. GALAKTIONOV, K., LEE, A.K., ECKSTEIN, J., DRAETTA, G., MECKLER, J., LODA, M. and BEACH, D., CDC25 phosphatases as potential human oncogenes. Science, 269, 1575-1577 (1995).
9. HARIGAI, M., MIYASHITA, T., HANADA, M. and REED, J.C., A cis-acting element in the bcl-2 gene controls expression through translational mechanisms. Oncogene, 12, 1369-1374 (1996).
10. ISAACS, J.T., Molecular markers for prostate cancer. Amer. J. Pathol., 150, 1511-1521 (1997).
11. KORSMEYER, S.J., Programmed cell death: bcl-2. In: Important advances in oncology, pp 19-28, Lippincott, Philadelphia (1993).
12. KRAJEWSKA, M., KRAJEWSKI, S., EPSTEIN, J.I., SHABAIK, A., SAUVAGEOT, J., SONG, K., KITADA, S. and REED, J.C., Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in prostate cancers. Amer. J. Pathol., 148, 1567-1576 (1996).
13. LIPPONEN, P. and VESALAINEN, S., Expression of the apoptosis suppressing protein Bcl-2 in prostatic adenocarcinoma is related to tumor malignancy. Prostate, 32, 9-15 (1997).
14. LODA, M., CUKOR, B., TAM, S.W., LAVIN, P., FIORENTINO, M., DRAETTA, G., JESSUP, M. and PAGANO, M., Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature (Med.), 3, 231-234 (1997).
15. LU, Q.L., ABEL, P., FOSTER, C. and LALANI, E.N., bcl-2: role in epithelial differentiation and oncogenesis. Hum. Pathol., 27, 102-110 (1996).
16. MATSUSHIMA, H., HOSAKA, Y., SUZUKI, M., MIZUTANI, T., ISHIZUKA, H. and KAWABE, K., Bcl-2 expression on prostate cancer and its relationship to cell cycle and prognosis. Int. J. Urol., 3, 113-117 (1996).
17. MCDONNEL, T.J., TRONCOSO, P., BRISBAY, S.M., LOGOTHETIS, C., CHUNG, L.W., HSIEH, J.T., TU, S.M. and CAMPBELL, M.L., Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52, 6940-6944 (1992).
18. MOUL, J.D., BETTENCOURT, M.C., SESTERHENN, I.A., MOSTOFI, F.K., MCLEOD, D.G., SRIVASTAVA, S. and BAUER, J.J., Protein expression of p53, Bcl-2 and Ki67 (Mib-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery, 120, 159-166 (1996).
19. MUIR, C.S., NECTOUX, J. and STASZEWSKI, J., The epidemiology of prostatic cancer: geographical distribution and time-trends. Acta Oncol., 30, 133- 140 (1990).
20. RAFFO, A.J., PERLMAN, H., CHEN, M.W., DAY, M., STREITMAN, J.S. and BUTTYAN, R., Overexpression of Bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer. Res., 55, 4438-4445 (1995).
21. SEGAL, N.H., COHEN, R.J., HAFFEJEE, Z. and SAVAGE, N., bcl-2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch. Pathol. Lab. Med., 118, 616-618 (1994).
22. SETO, M., JAEGER, U., HOCKETT, R.D., GRANINGER, W., BENNETT, S., GOLDMAN, P. and KORSMEYER, S.J., Alternative promoters and exons, somatic mutations and deregulation of the bcl-2-Ig fusion gene in lymphoma. EMBO J., 7, 123-131 (1988).
23. STATTIN, P., DAMBER, J.E., KARLBERG, L., NORDGREN, H. and BERGH, A., Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol. Res., 24, 257-264 (1996).
24. TANIGUCHI, J., MORIYAMA, N., KURIMOTO, S., KAMEYAMA, S. and KAWABE, K., Histochemical detection of intranuclear DNA fragmentation and its relation to the expression of Bcl-2 oncoprotein in human prostatic cancer. Brit. J. Urol., 77, 719-723 (1996).
25. TSUJIMOTO, Y. and CROCE, C.M., Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. nat. Acad. Sci. (Wash.), 83, 5214-5218 (1986).
26. YIN, X.M., OLTVAI, Z.N., VEIS-NOVACK, D.J., LINETTE, G.P. and KORSMEYER, S.J., bcl-2 gene family and the regulation of programmed cell death. Cold Spring Harbor Symp. Quant. Biol., 59, 387-393 (1994).
27. YOUNG, R.L. and KORSMEYER, S.J., A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol. cell. Biol., 13, 3686-3697 (1993).